TIBER CREEK GROUP for ASTELLAS PHARMA US, INC.
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 3rd Quarter - Report (this page) | Oct 20, 2016 | $60,000 | Replaced |
| 3rd Quarter - Amendment | Jan 24, 2017 | $60,000 | Replaced |
| 3rd Quarter - Amendment | Nov 13, 2017 | $60,000 | Yes |
What was lobbied
One issue area, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Issues related to the implementation of health care reform (P.L. 111-148, P.L. 111-152). Issues related to CMS Outpatient Prospective Payment System (OPPS) rule. H.R. 1178, Ensuring Equal Access to Treatments Act of 2015. S.1466, Ensuring Equal Access to Treatments Act of 2015. Issues related to march-in rights under Bayh-Dole Act (Pub. L. 96-517).
Foreign entity interest: Astellas Pharma, Inc. based in Tokyo, Japan and as identified in our Lobbying Registration, has an interest as a pharmaceutical company in all of the issues with respect to which Astellas Pharma US has lobbied and listed above.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN MICHAEL GONZALEZ | — |
| JONATHON JONES | — |
| SHEILA MURPHY | — |
| SEAN RICHARDSON | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.